The Vanguard S&P 500 exchange-traded fund has drawn investors with its industry-low costs, a strategy that has delivered strong results so far. At a 0.03% expense ratio, VOO costs about $3 per year on a Read more…
The artificial-intelligence boom is most often seen as a Wall Street story. Nvidia (NVDA) rallies. Big Tech spends billions. Data centers multiply. Investors debate which company will become the next major AI winner. But Bank Read more…
Intraday bias in GBP/JPY remains mildly on the upside at this point. Rise from 209.55 should target a retest on 219.56 high. On the downside, below 216.20 minor support will turn bias neutral and bring Read more…
Intraday bias in EUR/JPY is turned neutral first with current retreat, and some consolidations could be seen first. Further rally is expected as long as 183.90 support holds. Above 186.00 will extend the rise from Read more…
Intraday bias in EUR/GBP remains neutral at this point. While rebound from 0.8453 could extend, strong resistance should be seen from 0.8610 support turned resistance to limit upside. On the downside, break of 0.8530 support Read more…
Intraday bias in EUR/AUD stays neutral at this point. On the downside, firm break of 1.6250 will extend the fall from 1.6617 to retest 1.6108 low. On the upside, above 1.6444 will bring another rebound Read more…
Intraday bias in EUR/CHF stays neutral for more consolidations first. On the downside, below 0.9304 will extend the pullback from 0.9408 short term top. But downside should be contained by 38.2% retracement of 0.8979 to Read more…
The simple answer is no. I encourage investors to ignore all the fear-mongering headlines claiming that nearly half of the data centers planned for 2026 have been delayed or canceled. For quick background, New York Read more…
Are your credit cards actually working for you—or just draining your wallet with sky-high annual fees? In this episode, Nick Ewen, Editor-in-Chief of The Points Guy, breaks down everything you need to know about navigating Read more…
On August 19, Merck (MRK) said its personalized cancer vaccine had proved effective in a large, late-stage melanoma study, and Wall Street responded fast. Merck shares closed up about 12.5% that day, one of the Read more…